» Articles » PMID: 1712717

Low Dose Loop Diuretics in Essential Hypertension. Experience with Torasemide

Overview
Journal Drugs
Specialty Pharmacology
Date 1991 Jan 1
PMID 1712717
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Diuretics belong to the class of antihypertensive drugs recommended for first-line therapy of essential hypertension. Although they are widely and effectively used for the treatment of hypertension, the question remains whether their possible negative influence on metabolic and electrolyte parameters could partly offset the benefit of blood pressure reduction with respect to reduction of coronary artery disease. Recently published data demonstrate that much lower doses of thiazides exert the same antihypertensive effect as the higher doses used in the past and even prescribed today. These lower doses produce relatively little change in biochemical parameters. Thus, the postulated risks can be avoided by using the lowest effective dose. Traditionally, loop diuretics of the furosemide (frusemide) type are rarely used as first-line antihypertensive agents. They seem to display less efficacy coupled with an intense diuresis when used in standard available doses. However, there is evidence that newly developed loop diuretics, in lower doses than used in congestive heart failure, are effective antihypertensive agents. For example, torasemide 2.5mg once daily, which does not exert a significant diuresis over 24 hours compared with placebo, lowers elevated blood pressure to a similar extent than thiazides or related compounds. This antihypertensive effect is accompanied by less, if any, changes in metabolic or electrolyte parameters compared with widely used standard diuretics such as hydrochlorothiazide, indapamide or chlorthalidone. The influence on serum potassium and magnesium is similar to or even less than fixed combinations of hydrochlorothiazide and triamterene or amiloride. Thus, low-dose torasemide constitutes an alternative to established thiazide antihypertensive therapy.

Citing Articles

Loop Diuretics in the Treatment of Hypertension.

Malha L, Mann S Curr Hypertens Rep. 2016; 18(4):27.

PMID: 26951244 DOI: 10.1007/s11906-016-0636-7.


Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.

Mann S, Ernst M Curr Hypertens Rep. 2015; 17(4):542.

PMID: 25794956 DOI: 10.1007/s11906-015-0542-4.


Clinical pharmacokinetics and pharmacodynamics of torasemide.

Knauf H, Mutschler E Clin Pharmacokinet. 1998; 34(1):1-24.

PMID: 9474471 DOI: 10.2165/00003088-199834010-00001.


Benefits and risks of torasemide in congestive heart failure and essential hypertension.

Brater D Drug Saf. 1996; 14(2):104-20.

PMID: 8852525 DOI: 10.2165/00002018-199614020-00005.


Torasemide in comparison with thiazides in the treatment of hypertension.

Baumgart P Cardiovasc Drugs Ther. 1993; 7 Suppl 1:63-8.

PMID: 8435378 DOI: 10.1007/BF00877959.


References
1.
Lambe R, Kennedy O, Kenny M, Darragh A . Study of the tolerance and diuretic properties of torasemide following oral or intravenous administration to healthy volunteers. Eur J Clin Pharmacol. 1986; 31 Suppl:9-14. DOI: 10.1007/BF00541461. View

2.
Komajda M, Klimczak K, Boutin B, Brackman F, Guez D, Grosgogeat Y . Effects of indapamide on left ventricular mass and function in systemic hypertension with left ventricular hypertrophy. Am J Cardiol. 1990; 65(17):37H-42H. DOI: 10.1016/0002-9149(90)90340-7. View

3.
. The Captopril Prevention Project: a prospective intervention trial of angiotensin converting enzyme inhibition in the treatment of hypertension. The CAPPP Group. J Hypertens. 1990; 8(11):985-90. DOI: 10.1097/00004872-199011000-00002. View

4.
Thompson W . An assault on old friends: thiazide diuretics under siege. Am J Med Sci. 1990; 300(3):152-8; discussion 159-62. DOI: 10.1097/00000441-199009000-00005. View

5.
McVeigh G, Galloway D, Johnston D . The case for low dose diuretics in hypertension: comparison of low and conventional doses of cyclopenthiazide. BMJ. 1988; 297(6641):95-8. PMC: 1833832. DOI: 10.1136/bmj.297.6641.95. View